Consolidated Financial Results

for the Fiscal Year Ended June 20, 2021

[Japanese GAAP]

July 27, 2021

Company name: Genky DrugStores Co., Ltd.

Stock exchange listing: Tokyo Stock Exchange

Code number: 9267

URL: http://www.genkydrugstores.co.jp

Representative: Kenichi Fujinaga, President

Contact: Takeshi Tsunemi, Executive Officer, Treasurer and General Manager, IR Division

Phone: +81-776-67-5240

Scheduled date of convention of ordinary general meeting of shareholders: September 3, 2021

Scheduled date of commencing dividend payments: September 6, 2021

Scheduled date of filing annual securities report: September 6, 2021

Availability of supplementary briefing material on annual financial results: Available

Schedule of annual financial results briefing session: Scheduled (for institutional investors and analysts)

(Amounts of less than one million yen are rounded down.)

1. Consolidated Financial Results for the Fiscal Year Ended June 20, 2021 (June 21, 2020 to June 20, 2021)

(1) Consolidated Operating Results

(% indicates changes from the previous corresponding period.)

Net income

Net sales

Operating income

Ordinary income

attributable to owners

of parent

Million yen

%

Million yen

%

Million yen

%

Million yen

%

Fiscal 2020

142,376

15.2

6,294

45.0

6,601

44.6

4,831

75.4

Fiscal 2019

123,603

19.0

4,341

7.3

4,566

6.1

2,755

2.1

(Note) Comprehensive income: Fiscal 2020: ¥4,848 million (76.6%)

Fiscal 2019: ¥2,745 million (2.5%)

Net income

Diluted net

Net income to

Ordinary income

Operating income

shareholders'

per share

income per share

to total assets ratio

to net sales ratio

equity ratio

Yen

Yen

%

%

%

Fiscal 2020

318.35

318.03

16.2

7.6

4.4

Fiscal 2019

181.52

181.52

10.4

6.1

3.5

(Reference): Equity in earnings of affiliates: Fiscal 2020: ¥ million

Fiscal 2019: ¥ million

(2) Consolidated Financial Position

Total assets

Net assets

Equity ratio

Net assets per share

Million yen

Million yen

%

Yen

As of June 20, 2021

90,795

32,166

35.4

2,117.96

As of June 20, 2020

83,145

27,685

33.3

1,823.51

(Reference) Equity: As of June 20, 2021: ¥32,144 million As of June 20, 2020: ¥27,676 million

(3) Consolidated Cash Flows

Cash flow from

Cash flow from

Cash flow from

Cash and cash

equivalents at the end

operating activities

investing activities

financing activities

of the fiscal year

Million yen

Million yen

Million yen

Million yen

Fiscal 2020

12,075

(8,829)

(1,953)

7,913

Fiscal 2019

7,411

(11,222)

7,989

6,620

2. Dividends

Annual dividends

Total annual

Dividend

Dividend on

payout ratio

equity ratio

1st

2nd

3rd

Year-end

Total

dividends

(consolidated)

(consolidated)

quarter-end

quarter-end

quarter-end

Yen

Yen

Yen

Yen

Yen

Million yen

%

%

Fiscal 2019

12.50

12.50

25.00

379

13.8

1.4

Fiscal 2020

12.50

12.50

25.00

379

7.9

1.3

Fiscal 2021

12.50

12.50

25.00

8.0

(Forecast)

3. Consolidated Financial Results Forecast for the Fiscal Year Ending June 20, 2022 (June 21, 2021 to June 20, 2022)

(% indicates changes from

the previous

fiscal year.)

Net income

Net income

Net sales

Operating income

Ordinary income

attributable to

per share

owners of parent

Million yen

%

Million yen

%

Million yen

%

Million yen

%

Yen

First half

76,800

3,100

(4.1)

3,250

(5.0)

2,260

(7.2)

148.91

Full year

160,000

6,500

3.3

6,800

3.0

4,720

(2.3)

310.99

(Note) From the beginning of the fiscal year ending June 20, 2022, "Accounting Standard for Revenue Recognition" (ASBJ Statement No. 29), etc. will be applied, and the forecast is based on this standard. Therefore, the percentage of changes from the previous fiscal year in actual net sales before applying the standard is not presented.

Notes:

  1. Changes in significant subsidiaries during the period under review (changes in specified subsidiaries resulting in changes in scope of consolidation): No
    Newly consolidated: None (Company Name); Removed from consolidation: None (Company Name)
  2. Changes in accounting policies, changes in accounting estimates and retrospective restatement
    1. Changes in accounting policies due to the revision of accounting standards: No
    2. Changes in accounting policies other than 1) above: No
    3. Changes in accounting estimates: No
    4. Retrospective restatement: No
  3. Total number of issued shares (common stock)
  1. Total number of issued shares at the end of the period (including treasury stock): As of June 20, 2021: 15,477,484 shares
    As of June 20, 2020: 15,477,484 shares
  2. Total number of treasury stock at the end of the period:

As of June 20, 2021: 300,324 shares

As of June 20, 2020: 300,159 shares

  1. Average number of shares during the period: Year ended June 20, 2021: 15,177,219 shares Year ended June 20, 2020: 15,177,335 shares

(Reference) Summary of Non-Consolidated Financial Results

Non-Consolidated Financial Results for the Fiscal Year Ended June 20, 2021 (June 21, 2020 to June 20, 2021)

(1) Non-Consolidated Operating Results

(% indicates changes from the previous fiscal year.)

Net sales

Operating income

Ordinary income

Net income

Million yen

%

Million yen

%

Million yen

%

Million yen

%

Fiscal 2020

318

18.1

141

153.1

220

193.1

132

331.6

Fiscal 2019

269

10.0

55

541.2

75

137.0

30

348.8

Net income per share

Diluted net income

per share

Yen

Yen

Fiscal 2020

8.71

8.70

Fiscal 2019

2.02

2.02

(2) Non-Consolidated Financial Position

Total assets

Net assets

Equity ratio

Net assets per share

Million yen

Million yen

%

Yen

As of June 20, 2021

23,260

21,343

91.7

1,404.84

As of June 20, 2020

23,092

21,578

93.4

1,421.16

(Reference) Equity: As of June 20, 2021: ¥21,321 million As of June 20, 2020: ¥21,569 million

  • These financial results are outside the scope of audit by a certified public accountant or an audit corporation.
  • Explanation of the proper use of financial results forecast and other notes

The earnings forecasts and other forward-looking statements herein are based on information that is available and certain assumptions deemed reasonable as of the date of publication of this document. Actual results may differ significantly from these forecasts due to a wide range of factors.

Attachments

  • Original document
  • Permalink

Disclaimer

Genky DrugStores Co. Ltd. published this content on 27 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2021 06:09:05 UTC.